Please assess the completion status of the following clinical trial:

Trial Title: PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed, unresectable urothelial carcinoma of the bladder or the upper urinary tract~* Wild-type HRAS~* Male and female subjects \> 18 years of age~* General condition ECOG 0-1~* Life expectancy at least 12 weeks~* Women of child-bearing potential: negative pregnancy test and use of effective contraception(oral contraceptive, coil); men: use of adequate male contraception (condom) for up to 3 months after discontinuation of panitumumab therapy~* Locally advanced or metastatic disease (T3b,T4 and/or N+ and/or M+)~* At least one unidimensionally measurable lesion detectable in CT or MRI corresponding to the RECIST criteria~* Adequate haematological, hepatic, renal and metabolic function parameters:~Leukocytes \> 3000/mm³, ANC ≥ 1500/mm³, platelets ≥ 100,000/mm³, hemoglobin \> 9 g/dl Creatinine clearance ≥ 50 ml/min and serum creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases, AP ≤ 5 x upper limit of normal Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal INR and PTT \< 1.5 x the upper limit of the normal reference range~Exclusion Criteria:~* HRAS mutation~* Absence of any of the above-listed inclusion criteria~* Dialysis-dependence following nephrectomy~* Patients with cerebral tumours and/or cerebral metastases~* Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment.~* Patients with uncontrolled hypertension; systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 90 mmHg despite optimal medical treatment~* History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.~* Patients with thrombotic or embolic events, such as stroke or pulmonary embolism~* Patients with recent or known history of haemorrhagic diathesis~* Known significant neurological or psychiatric disorders, including dementia and epileptic seizures~* Serious inflammatory eye conditions, hearing impairment~* Pulmonary (pO2 \< 60 mmHg), haemopoietic (e.g. serious bone marrow aplasia), hepatic or renal disorders~* Patients with poorly controlled diabetes mellitus~* Serious bacterial or fungal infections (\>grade 2 NCI CTC Version 3)~* Chronic hepatitis B or C; HIV infection~* Autoimmune disease~* Allergic reaction to one of the medications to be used~* Status post organ transplantation~* Status post autologous bone marrow transplantation or stem cell transplantation in the 4 months prior to study commencement~* Manifest secondary malignancy or other form of cancer in the previous 5 years (excluding basalioma, in situ cervical cancer, incidental prostatic cancer)~* Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment~* Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 3 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly).~* Active participation in other clinical studies in the previous 4 weeks~* Prior systemic therapy with cytostatics or immunotherapeutic agents~* Concurrent use of other anticancer treatments after study commencement~* Intravesical chemotherapy in the previous 4 weeks~* Radiotherapy in the previous 4 weeks~* Previous radiotherapy in which all lesions to be used for the evaluation of tumour response were irradiated~* Patients in a closed institution according to an authority or court decision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (GemCis + Panitumumab) (Type: EXPERIMENTAL): gemcitabine + cisplatin + panitumumab
- Arm B (GemCis) (Type: ACTIVE_COMPARATOR): gemcitabine + cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).